Revelation Biosciences, Inc. (REVB)
| Market Cap | 5.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.08M |
| Shares Out | 5.92M |
| EPS (ttm) | -14.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,105 |
| Open | 0.8466 |
| Previous Close | 0.8500 |
| Day's Range | 0.8310 - 0.8799 |
| 52-Week Range | 0.8301 - 60.4800 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2025 |
About REVB
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in Janua... [Read more]
Financial Performance
Financial StatementsNews
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing ...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebal...
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammat...
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammat...
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamm...
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - D...
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamma...
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - D...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (Nasdaq: REVB) the “Company” or “Revelation”) a clinical-stage life sciences company focused on rebalancing inflammation to opti...
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to op...
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reve...
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing infla...
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflamm...
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-...
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power o...
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the powe...